<DOC>
	<DOCNO>NCT02192463</DOCNO>
	<brief_summary>Study determine relative bioavailability different oral Viramune Extended Release ( ER ) formulation compare Viramune® Immediate Release ( IR ) tablet</brief_summary>
	<brief_title>Relative Bioavailability Different Oral Viramune Extended Release Formulations Compared Viramune® Oral Suspension Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Healthy male accord follow criterion base upon complete medical history , include physical examination , vital sign ( Blood Pressure ( BP ) , Pulse Rate ( PR ) ) , 12lead electrocardiogram ( ECG ) , clinical laboratory Age ≥18 Age ≤50 year Body Mass Index ( BMI ) ≥18.5 BMI ≤29.9 kg/m2 Signed date write informed consent prior admission study accordance Good Clinical Practice local legislation Any finding medical examination ( include BP , PR ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder clinical relevance Surgery gastrointestinal tract ( except appendectomy herniotomy ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder History relevant orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History relevant allergy/hypersensitivity ( include allergy drug excipients ) Intake drug long halflife ( &gt; 24 hour ) within least one month le 10 halflives respective drug prior administration trial Use drug might reasonably influence result trial base knowledge time protocol preparation within 10 day prior administration trial Participation another trial investigational drug within two month prior administration trial Smoker ( &gt; 10 cigarette &gt; 3 cigar &gt; 3 pipes/day ) Inability refrain smoke trial day Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( 100 mL within four week prior administration trial ) Excessive physical activity ( within one week prior administration trial ) Any laboratory value outside reference range clinical relevance Inability comply dietary regimen trial site A marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration correct QT interval ( QTc ) &gt; 450 m ) A history additional risk factor torsade de pointes ( e.g. , heart failure , hypokalemia , family history Long QT Syndrome ) History disease affect present situation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>